Pancreatic Adenocarcinoma
David P. Ryan, Theodore Sunki Hong, Nabeel M. Bardeesy · New England Journal of Medicine · 2014
Cancer of the pancreas is predominantly adenocarcinoma and involves activating KRAS mutations in the large majority of cases. Surgical resection can be effective in localized disease; combination chemotherapy offers some palliation in advanced disease.
Cited by 2,305 works. doi:10.1056/nejmra1404198
Authors
References
- Global cancer statistics
- Cancer statistics, 2014
- Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
- Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
- Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group
- A Randomized Trial of Chemoradiotherapy and Chemotherapy after Resection of Pancreatic Cancer
- Incidence of Cancer in 161 Families Affected by Ataxia–Telangiectasia
- Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer
- Adjuvant Radiotherapy and 5-Fluorouracil After Curative Resection of Cancer of the Pancreas and Periampullary Region